Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 554

1.

Brief Fixation and Hormone Receptor Expression in Breast Cancer.

Lee AH, Rakha EA, Ellis IO.

Am J Surg Pathol. 2015 Jan 9. [Epub ahead of print] No abstract available.

PMID:
25581734
[PubMed - as supplied by publisher]
2.

Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer.

Davis J, Martin SG, Patel PM, Green AR, Rakha EA, Ellis IO, Storr SJ.

BMC Cancer. 2014 Dec 23;14(1):995. doi: 10.1186/1471-2407-14-995.

PMID:
25539577
[PubMed - in process]
Free Article
3.

Biological and clinical significance of PARP1 protein expression in breast cancer.

Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2014 Dec 21. [Epub ahead of print]

PMID:
25528020
[PubMed - as supplied by publisher]
4.

Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer.

Abdel-Fatah TM, Ball G, Lee AH, Pinder SE, Macmillan RD, Cornford E, Moseley PM, Silverman R, Price J, Latham B, Palmer D, Chan A, Ellis IO, Chan S.

Clin Cancer Res. 2014 Dec 17. pii: clincanres.0685.2014. [Epub ahead of print]

PMID:
25520390
[PubMed - as supplied by publisher]
5.

Updated UK Recommendations for HER2 assessment in breast cancer.

Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO; National Coordinating Committee for Breast Pathology.

J Clin Pathol. 2015 Feb;68(2):93-9. doi: 10.1136/jclinpath-2014-202571. Epub 2014 Dec 8.

PMID:
25488926
[PubMed - in process]
Free Article
6.

Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.

Abdel-Fatah TM, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, Rakha E, Ball G, Ellis IO, Curtin NJ, Madhusudan S.

Mol Oncol. 2014 Nov 6. pii: S1574-7891(14)00262-2. doi: 10.1016/j.molonc.2014.10.013. [Epub ahead of print]

PMID:
25468710
[PubMed - as supplied by publisher]
7.

Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy.

Zhang Y, Storr SJ, Johnson K, Green AR, Rakha EA, Ellis IO, Morgan DA, Martin SG.

Oncotarget. 2014 Dec 30;5(24):12936-49.

PMID:
25427448
[PubMed - in process]
Free Article
8.

Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.

Abdel-Fatah TM, Arora A, Alsubhi N, Agarwal D, Moseley PM, Perry C, Doherty R, Chan SY, Green AR, Rakha E, Ball G, Ellis IO, Madhusudan S.

Neoplasia. 2014 Nov 20;16(11):982-91. doi: 10.1016/j.neo.2014.09.009. eCollection 2014 Nov.

PMID:
25425972
[PubMed - in process]
Free PMC Article
9.

Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study.

Rakha EA, Tan PH, Varga Z, Tse GM, Shaaban AM, Climent F, van Deurzen CH, Purnell D, Dodwell D, Chan T, Ellis IO.

Br J Cancer. 2015 Jan 20;112(2):283-9. doi: 10.1038/bjc.2014.592. Epub 2014 Nov 25.

PMID:
25422911
[PubMed - in process]
10.

High-grade encapsulated papillary carcinoma of the breast: an under-recognized entity.

Rakha EA, Varga Z, Elsheik S, Ellis IO.

Histopathology. 2014 Nov 8. doi: 10.1111/his.12591. [Epub ahead of print]

PMID:
25382726
[PubMed - as supplied by publisher]
11.

The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis.

Ullenhag GJ, Al-Attar A, Mukherjee A, Green AR, Ellis IO, Durrant LG.

J Cancer Res Clin Oncol. 2014 Sep 18. [Epub ahead of print]

PMID:
25230899
[PubMed - as supplied by publisher]
12.

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.

Albarakati N, Abdel-Fatah TM, Doherty R, Russell R, Agarwal D, Moseley P, Perry C, Arora A, Alsubhi N, Seedhouse C, Rakha EA, Green A, Ball G, Chan S, Caldas C, Ellis IO, Madhusudan S.

Mol Oncol. 2015 Jan;9(1):204-17. doi: 10.1016/j.molonc.2014.08.001. Epub 2014 Aug 27.

PMID:
25205036
[PubMed - in process]
13.

A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C.

Mol Oncol. 2015 Jan;9(1):115-27. doi: 10.1016/j.molonc.2014.07.019. Epub 2014 Aug 8.

PMID:
25169931
[PubMed - in process]
Free PMC Article
14.

A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts.

Mathew J, Lee S, Syed BM, Morgan DA, Ellis IO, Cheung KL.

Breast Cancer Res Treat. 2014 Oct;147(3):671-4. doi: 10.1007/s10549-014-3094-4. Epub 2014 Aug 23.

PMID:
25148877
[PubMed - in process]
15.

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer.

Rudraraju B, Droog M, Abdel-Fatah TM, Zwart W, Giannoudis A, Malki MI, Moore D, Patel H, Shaw J, Ellis IO, Chan S, Brooke GN, Nevedomskaya E, Lo Nigro C, Carroll J, Coombes RC, Bevan C, Ali S, Palmieri C.

Breast Cancer Res Treat. 2014 Sep;147(2):295-309. doi: 10.1007/s10549-014-3098-0. Epub 2014 Aug 22.

PMID:
25141981
[PubMed - in process]
16.

Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?

Abdel-Fatah TM, Perry C, Arora A, Thompson N, Doherty R, Moseley PM, Green AR, Chan SY, Ellis IO, Madhusudan S.

Antioxid Redox Signal. 2014 Dec 1;21(16):2262-8. doi: 10.1089/ars.2014.6077. Epub 2014 Sep 22.

PMID:
25111287
[PubMed - in process]
17.

ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer.

Jerjees DA, Alabdullah M, Alkaabi M, Abduljabbar R, Muftah A, Nolan C, Green AR, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2014 Aug;147(1):25-37. doi: 10.1007/s10549-014-3066-8. Epub 2014 Aug 2.

PMID:
25085753
[PubMed - in process]
18.

Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts.

Syed BM, Green AR, Nolan CC, Morgan DA, Ellis IO, Cheung KL.

PLoS One. 2014 Jul 7;9(7):e100573. doi: 10.1371/journal.pone.0100573. eCollection 2014.

PMID:
24999743
[PubMed - in process]
Free PMC Article
19.

Therapeutic targeting of integrin αvβ6 in breast cancer.

Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan L, Gillett C, Brentnall A, Violette S, Weinreb PH, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF.

J Natl Cancer Inst. 2014 Jun 28;106(8). pii: dju169. doi: 10.1093/jnci/dju169. Print 2014 Aug.

PMID:
24974129
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers.

Abdel-Fatah T, Arora A, Agarwal D, Moseley P, Perry C, Thompson N, Green AR, Rakha E, Chan S, Ball G, Ellis IO, Madhusudan S.

Breast Cancer Res Treat. 2014 Jul;146(2):309-20. doi: 10.1007/s10549-014-3035-2. Epub 2014 Jun 28.

PMID:
24972688
[PubMed - in process]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk